Abiraterone acetate (trade name: Zytiga) is a prodrug used, in combination with prednisone, for the treatment of prostate cancer. Commercial abiraterone acetate crystallizes in the orthorhombic space group P212121 with a = 7.525265(14), b = 9.733111(16), c = 30.22909(10) Å, V = 2214.106(7) Å3, and Z = 4. A reduced cell search in the Cambridge Structural Database (Groom et al., Reference Groom, Bruno, Lightfoot and Ward2016) yielded a previously reported crystal structure (Zhou et al., Reference Zhou, Huang and Huang2015) collected at 283 K. In this work, the sample was ordered from Carbosynth and analyzed as received. The room-temperature crystal structure was refined using synchrotron (λ = 0.413691 Å) powder diffraction data, density functional theory, and Rietveld refinement techniques. The diffraction data were collected on beamline 11-BM at the Advanced Photon Source, Argonne National Laboratory. Figure 1 shows the powder X-ray diffraction pattern of the compound. The crystal structure is dominated by van der Waals interactions and electrostatic forces. There are no hydrogen bonds. The pattern is included in the Powder Diffraction File as entry 00-065-1409.
Figure 1. (Color online) Powder X-ray diffraction pattern of abiraterone acetate.
SUPPLEMENTARY MATERIAL
The supplementary material for this article can be found at https://doi.org/10.1017/S0885715618000015.
ACKNOWLEDGEMENTS
Use of the Advanced Photon Source at Argonne National Laboratory was supported by the U. S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357. This work was partially supported by the International Centre for Diffraction Data. We thank Lynn Ribaud for his assistance in data collection.
